BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Novacea, Inc. (Acquired by Transcept Pharmaceuticals, Inc.) 

400 Oyster Point Boulevard
Suite 200
South San Francisco  California  94080  U.S.A.
Phone: 650-228-1080 Fax: 650-228-1088


View Clinical Trials from BioPharm Insight

Novacea, Inc. (NASDAQ: NOVC), located in South San Francisco, California, is a biopharmaceutical company focused on in-licensing, developing and commercializing novel therapies for the treatment of cancer. We currently have two clinical-stage oncology product candidates. Our lead product candidate, Asentarâ„¢ (DN-101), is part of an exclusive worldwide development and commercialization agreement with Schering Plough Corporation. Asentar is currently in a Phase 3 clinical trial for the treatment of androgen-independent prostate cancer, and a Phase 2 trial for the treatment of advanced pancreatic cancer. Our second product candidate, AQ4N, is being investigated in combination with radiation and chemotherapy in a Phase 1/2 clinical trial of patients with newly diagnosed glioblastoma multiforme and a Phase 2 trial for patients with acute lumphoblastic leukemia.

Our experienced team uses its expertise in oncology product development to identify, license and develop novel therapeutics with the potential to improve clinical outcomes for cancer patients. We believe that our oncology development expertise enables our team to design efficient clinical development and commercialization programs that could provide cancer patients with improved treatment options over current standards of care.

Last Updated: 11-01-2007

 Key Statistics

Ownership: Public

Web Site: Novacea, Inc. (Acquired by Transcept Pharmaceuticals, Inc.)
Symbol: TSPT

 Company News
Transcept Pharmaceuticals, Inc. Completes Merger with Novacea, Inc. (NOVC) Commences Trading on NASDAQ Under New Ticker 'TSPT' 2/2/2009 8:53:44 AM
Novacea, Inc. (NOVC) Stockholders Approve Merger With Transcept Pharmaceuticals, Inc. 1/27/2009 12:12:06 PM
Institutional Shareholder Services and Glass Lewis Recommend Novacea, Inc. (NOVC) Stockholders Vote 1/20/2009 9:28:24 AM
Novacea, Inc. (NOVC) Schedules Special Meeting of Stockholders for Vote on Merger With Transcept Pharmaceuticals, Inc. 1/7/2009 10:09:46 AM
Novacea, Inc. (NOVC) Reports Third Quarter 2008 Financial Results 11/11/2008 10:42:47 AM
Novacea, Inc. (NOVC) and Transcept Pharmaceuticals, Inc. Announce Filing of Form S-4 Proxy/Registration Statement 10/6/2008 9:27:15 AM
Novacea, Inc. (NOVC) Says Not to Develop Drug after FDA Lifts Hold 9/10/2008 3:32:48 PM
Reverse Mergers Throw Lifeline To Struggling Biotechs 9/8/2008 7:14:10 AM
Novacea, Inc. (NOVC) and Transcept Pharmaceuticals, Inc. to Hold Conference Call to Discuss Signing of Merger Agreement 9/2/2008 10:39:01 AM
Novacea, Inc. (NOVC) to be Acquired by Transcept Pharmaceuticals, Inc. 9/2/2008 6:19:30 AM